



Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016

Weekending:- 17-08-2018

Legal Publication Date:- 07-09-2018

Journal Code (180907)



NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

13-08-2018		
553/2018	Syngenta Participations AG Switzerland (Priority 17-08-2017 IN)	“HERBICIDAL COMPOUNDS”
554/2018	CORN PRODUCTS DEVELOPMENT, INC. USA (Priority 21-08-2017 US)	“MALTOSE SYRUPS, COMESTIBLES COMPRISING THE SYRUP, AND PROCESS FOR MAKING THE SAME”
555/2018	CORN PRODUCTS DEVELOPMENT, INC. USA (Priority 15-08-2017 US)	“Liquid and Powder Low Viscosity 17- 20 DE Maltodextrin”
556/2018	Arvind Limited, India (Priority 24-08-2017 IN)	“A NON-WOVEN APPAREL FABRIC, AND A PROCESS FOR MANUFACTURING THE SAME”
15-08-2018		
557/2018	Dr. Syed Muhammad Alamdar Raza NUST - Rawalpindi Zubair Yamin Rana Dr. Imran Shafi Khurram Mahmood NUST – Rawalpindi Pakistan	“Special service tool -007 for repair of 14.5mm Gun”
558/2018	Dr. Syed Muhammad Alamdar Raza Rawalpindi - Pakistan	“TRAINING & EVALUATION EQUIPMENT SIMULATOR”

	Abdur Rafe Hasan Lahore Zubair Yameen Rana Rawalpindi -Pakistan	
559/2018	Dr. Syed Muhammad Alamdar Raza Rawalpindi - Pakistan Abdur Rafe Hasan Lahore Zubair Yameen Rana Rawalpindi -Pakistan	"IDENTIFICATION OF FRIEND OR FOE FOR LAND MINES"
560/2018	Dr. Imran Shafi NUST – Rawalpindi Dr. Jamil Ahmed Kohat - Pakistan	"Modification of Volume control of M3AR & GB6500 in AH-IF Helicopter"
561/2018	Saurer Technologies GmbH & Co. KG Germany (Priority 16-08-2017 DE)	"TEXTILE MACHINES THAT PRODUCE TAKE-UP PACKAGES"
562/2018	Inflazome Limited Ireland (Priority 15-08-2017 GB)	"NOVEL COMPOUNDS"
563/2018	Inflazome Limited Ireland (Priority 15-08-2017 GB)	"NOVEL COMPOUNDS"
564/2018	AbbVie Inc., USA AbbVie Deutschland GmbH & Co. KG, Germany (Priority 15-08-2017 US)	"MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE"
565/2018	Inflazome Limited Ireland (Priority 15-08-2017 GB)	"NOVEL COMPOUNDS"

566/2018	AbbVie Inc., USA AbbVie Deutschland GmbH & Co. KG, Germany (Priority 15-08-2017 US)	"MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE"
567/2018	AbbVie Inc., USA AbbVie Deutschland GmbH & Co. KG, Germany (Priority 15-08-2017 US)	"MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE"
16-08-2018		
568/2018	Dr. Kashif Ahmed Muhammad Hayat Karachi – Pakistan	"New Test Method for Automatic Potentiometric Determination of Total Acid Number in Transformer/Insulating Oil"
569/2018	SICPA HOLDING SA, Switzerland (Priority 25-08-2017 EP)	"ASSEMBLIES AND PROCESSES FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING ORIENTED NON-SPHERICAL OBLATE MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES"
570/2018	SICPA HOLDING SA, Switzerland (Priority 25-08-2017 EP)	"ASSEMBLIES AND PROCESSES FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING ORIENTED NON-SPHERICAL OBLATE MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES"
571/2018	SICPA HOLDING SA,	"ASSEMBLIES AND PROCESSES

	Switzerland (Priority 25-08-2017 EP)	FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING ORIENTED NON-SPHERICAL OBLATE MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES"
572/2018	Dr. Syed Muhammad Alamdar Raza Dr. Muhammad Khurram Kiyani Imran Khan Niazi Rawalpindi -Pakistan	"Vertical Guidance Tester"
573/2018	Dr. Syed Muhammad Alamdar Raza Dr. Muhammad Khurram Kiyani Imran Khan Niazi Rawalpindi -Pakistan	"Angle Limiter Tester"
574/2018	Dr. Syed Muhammad Alamdar Raza Dr. Muhammad Khurram Kiyani Imran Khan Niazi Rawalpindi -Pakistan	"Gun Locking Device Tester"
575/2018	Dr. Syed Muhammad Alamdar Raza Dr. Muhammad Khurram Kiyani Imran Khan Niazi Rawalpindi -Pakistan	"Tilt Angle Indicator"
576/2018	Dr. Syed Muhammad Alamdar Raza Dr. Muhammad Khurram Kiyani Faheem Iftikhar Waqas Ali Mahrukh Mohsin Arslan Malik Ghulam Abbas Rawalpindi -Pakistan	"IIT Classifier Based on Black Spot Detection through Image Processing"
577/2018	Dr. Syed Muhammad Alamdar Raza Dr. Muhammad Khurram Kiyani Faheem Iftikhar Waqas Ali	"Universal DC-DC Converter for Communication Equipment"

	Mahrukh Mohsin Arslan Malik Ghulam Abbas Rawalpindi -Pakistan	
578/2018	Doctor Syed Muhammad Alamdar Raza Doctor Muhammad Khurram Kiyani Ahmed Hassan Taimoor Technician Muhammad Ramzan Technician Muhammad Nawaz Technician Zulfiqar Ahmed Technician Wahid Hussain Technician Qaiser Imran Rawalpindi -Pakistan	"Backup Power Supply of MARWIN Set MW-12A"
579/2018	Doctor Syed Muhammad Alamdar Raza Doctor Muhammad Khurram Kiyani Ahmed Hassan Taimoor Technician Muhammad Ramzan Technician Imam Ud Din Technician Imtiaz Ahmed Technician Qaiser Farooq Technician Nizakat Ali Rawalpindi -Pakistan	"Modulator Power Supply of AN/TPQ- 36 Radar"
580/2018	Novo Nordisk A/S Denmark (Priority 17-08-2017 EP)	"NOVEL ACYLATED INSULIN ANALOGUES AND USES THEREOF"
17-08-2018		
581/2018	Saif Ullah Islamabad - Pakistan	"Headset with Multiple Adjustable Dry Electrodes for Electrophysiological Signals Measurement and Brain Function Diagnostic Test"


APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.



The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.


The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


802/2010	SANOFI-AVENTIS France.	<p>"SUBSTITUTED 5-PHENYLPYRAZOLOPYRIDINE COMPOUND"</p> <p>A61K31/437 and C07D471/06.</p> <p style="text-align: right;">142895</p> <p>Compound of formula (I):</p> <div style="text-align: center;">  <p style="text-align: right;">(I)</p> </div> <p>in which: R¹ represents a phenyl group or naphthyl group, optionally substituted by one or more atoms or groups chosen, independently of one another, from: halogen, (C₁-C₆)alkyl, halo(C₁-C₆)alkyl, (C₁-C₆)alkoxy, halo(C₁-C₆)alkoxy, (C₁-C₆)thioalkyl, -S(O)(C₁-C₆)alkyl, -S(O)₂(C₁-C₆)alkyl, hydroxyl, hydroxy(C₁-C₆)alkylene, CHO, COOH, (C₁-C₆)alkoxy(C₁-C₆)alkyleneoxy, NR_aR_b, CONR_aR_b, SO₂NR_aR_b, NR_cCOR_d,</p>
----------	---------------------------	---


		<p>OC(O)NRaRb, OCO(C₁-C₆)alkyl, NRcC(O)ORe or NRcSO₂Re; X represents from 1 to 4 substituents which are identical to or different from one another and which are chosen from hydrogen, halogen, (C₁-C₆)alkyl or (C₁-C₆)alkoxy, it being possible for the (C₁-C₆)alkyl to be optionally substituted by one or more groups chosen from a halogen, (C₁-C₆)alkoxy or hydroxyl; R² and R³ represent, independently of one another, a hydrogen atom, a (C₁-C₆)alkyl group optionally substituted by an R_f group, or a CHO or COOH group; X and R³ can together form, with the carbon atoms which carry them, a carbocycle of 5 to 7 carbon atoms; R₄ represents a hydrogen atom or a (C₁-C₆)alkyl group; R_a and R_b represent, independently of one another, a hydrogen atom or a (C₁-C₆)alkyl, aryl(C₁-C₆)alkylene or aryl group; or R_a and R_b together form, with the nitrogen atom which carries them, an azetidine, pyrrolidine, piperidine, azepine, morpholine, thiomorpholine, piperazine or homopiperazine group, this group being optionally substituted by a (C₁-C₆)alkyl, aryl or aryl(C₁-C₆)alkylene group; R_c and R_d represent, independently of one another, a hydrogen atom or a (C₁-C₆)alkyl, aryl(C₁-C₆)alkylene or aryl group; or R_c and R_d together form a (C₂-C₅)alkylene group; R_e represents a (C₁-C₆)alkyl, aryl(C₁-C₆)alkylene or aryl group; or R_c and R_e together form a (C₂-C₅)alkylene group; R_f represents a hydroxyl, oxo, CHO or COOH group, pharmaceutical composition comprising thereof for the treatment or prevention of neurodegenerative diseases and synthetic process.</p>
<p>49/2011</p>	<p>BOEHRINGER INGELHEIM INTERNATIONAL GmbH Germany.</p>	<p>"{3,5-Dimethyl- 1- [4-(4-trifluoromethyl-benzoylamino)-benzyl] -1H-pyrazol-4-yl}-acetic acid"</p> <p>A61K31/415, A61P29/00, A61P37/00 and C07D231/12</p> <p style="text-align: right;">142896</p> <p>The present invention relates to pyrazole compound of formula (I) having CRTH2-activity</p>

		 <p style="text-align: right;">(I)</p> <p>wherein W, L¹, L², X, L³, Y, R¹ and R² are as defined in the specification and claims, and to pharmaceutical composition containing said compound or containing a combination of said compound with one or more active substances.</p>
<p>336/2011</p>	<p>CASALE CHEMICALS S.A., Switzerland.</p>	<p>"PROCESS FOR THE PRODUCTION OF LIGHT OLEFIN FROM SYNTHESIS GAS"</p> <p>C07C1/04, C07C11/04, C07C11/06, C07C11/08</p> <p style="text-align: right;">142897</p> <p>A new process for light-olefins production is disclosed. The process comprises the step of contacting syngas with a iron-based catalyst at a temperature in the range from 250 °C to 350 °C and at a pressure in the range from 10 bar to 40 bar. By so doing a production of light olefins with a selectivity of at least 80% is obtained.</p>
<p>3/2012</p>	<p>LES LABORATOIRES SERVIER France.</p>	<p>"NEW PROCESS FOR THE SYNTHESIS OF N-[2-(7-METHOXY-1-NAPHTHYL)ETHYL]ACETAMIDE (AGOMELATINE)"</p> <p>C07C231/14, C07C233/18, C07C233/31 and C07D 209/48</p> <p style="text-align: right;">142898</p> <p>Process for the industrial synthesis of the agomelatine of formula (I)</p>  <p style="text-align: right;">(I)</p>

		<p>using free radical reactions and starting from 1 - (4-methoxyphenyl)-4-penten-1 one of formula</p>  <p>(II):</p>
757/2012	SICPA HOLDING SA, Switzerland.	<p>"POLYMER-BONDED POLYCYCLIC AROMATIC HYDROCARBON HAVING NITROGEN CONTAINING SUBSTITUENT"</p> <p>C09D11/103 and C09D11/328</p> <p style="text-align: right;">142899</p> <p>The invention concerns a polymer-bonded polycyclic aromatic hydrocarbon compound of general formula (I): $(P-O)_x - Q - (Y)_w$ (I) wherein P represents a polymeric moiety having at least three repeating units which comprise an optionally substituted phenyl ring; Q represents a perylene, quaterrylene or terrylene moiety; Y is selected from (i) halogen and(ii) optionally substituted N-heterocycloaliphatic groups having from 3 to about 8 ring members which are bonded to Q through an N atom, provided that at least one Y represents(ii); x represents an integer of from 1 to 4; w represents an integer of from 1 to 4. The invention further concerns a process for making such a compound,a printing ink composition comprising such compound,as well as a marking or security feature made with such ink composition.</p>
592/2013	CASALE CHEMICALS S.A., Switzerland.	<p>"Burner for the production of synthesis gas"</p> <p>C01B3/36</p> <p style="text-align: right;">142900</p> <p>A burner suitable for the over stoichiometric combustion of a hydrocarbon source, comprising a nozzle (2) for the formation of a diffusion flame outside the burner, and said nozzle (2) comprising</p>

		<p>one (20) or more (21, 22) tubular bodies which define a channel (25) or a plurality of coaxial channels (23, 24) for respective reactant streams, wherein the or each of the tubular bodies forming said nozzle (2) are made of a technical ceramic material.</p>
677/2013	SANOFI France.	<p>"EXENDIN-4 PEPTIDIC COMPOUNDS AS DUAL GLP-1/GLUCAGON AGONISTS"</p> <p>C07K14/575.</p> <p style="text-align: right;">142901</p> <p>The present invention relates to exendin-4 peptidic compound which potently activate the GLP1 and the glucagon receptor. In these</p> <p>exendin-4 derivatives - among other substitutions - methionine at position 14 is replaced by an amino acid carrying an —NH₂ group in the side chain, which is further substituted with an unpolar residue (e.g. a fatty acid optionally combined with a linker). The invention provides a peptidic compound having the formula (I): R¹-Z-R² (I) wherein the definitions of the variables are recited in the claims of specification. The exendin-4 peptidic compound medically useful, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.</p>
854/2013	PFIZER LIMITED England.	<p>"4-(BIPHENYL-3-YL)-7H-IMIDAZO [4,5-C] PYRIDAZINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF"</p> <p>C07D487/04.</p> <p style="text-align: right;">142902</p> <p>The present invention relates to a compound of formula (I):</p>

		<div style="text-align: center;">  <p>(I)</p> </div> <p>wherein R¹ is selected from (C₁-C₄)alkyl, (C₃-C₄)cycloalkyl, NH₂, and NH(C₁-C₄)alkyl and R² is H; or R¹ and R² together are —CH₂-CH₂- or —N(CH₃)-CH₂-; R³ is selected from H, F, CHF₂, OCH₃ and CN; R⁴ is selected from H, F, Cl, OH, OCH₃ and CN; and R⁵ is selected from (C₂-C₄)alkyl, (C₃-C₅)cycloalkyl and methyl-substituted (C₃-C₅)cycloalkyl. The compound of present invention is imidazopyridazine, more particularly 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine compound. The present invention further provides a pharmaceutical composition of the compound of formula (I) along with a pharmaceutically acceptable excipient. The compound of the present invention modulates the activity of the GABA_A receptor and useful as analgesic drug for the treatment of pain.</p>
<p>271/2015</p>	<p>ANDRITZ HYDRO GmbH Austria.</p>	<p>"PLANT FOR GENERATING ELECTRIC POWER FROM A FLOWING MEDIUM"</p> <p>E02B8/00, E02B9/00 and F03B13/10</p> <p style="text-align: right;">142903</p> <p>The invention relates to a plant for generating electric power from a flowing medium, e.g. water. The invention is primarily characterised in that one or more turbine generator units (1) are provided in the diversion tunnel (2) of a weir system. In this way, a diversion tunnel that is normally closed off after construction work has been completed can be used to generate energy.</p>

		
<p>27/2016</p>	<p>Zain Ul Abideen Ahsan C/o M/s. Vision Technologies Corporation(Pvt), Limited, Pakistan.</p>	<p>"SPORT BALL AND METHOD OF MANUFACTURING SPORT BALL"</p> <p>A63B41/08</p> <p style="text-align: right;">142904</p> <p>A method for manufacturing a sports ball comprises cutting outer panels and inner padding cut-outs from three different sheet materials. The padding layer materials have perforations. A layer of heat-reactive adhesive that expands upon heating is applied in the machine-stitched seam areas before the panels are stitched together. The padding layer is glued to the inside-out ball cover before the cover is turned right-side out. A reinforced bladder is inserted into the cover, the remaining seams are stitched shut, and then the ball is molded in a heat and pressure mold that causes the seams to be welded as well as stitched, due to the expansion of the heat-reactive adhesive to cover the stitching in the seams. Enhanced performance characteristics of the resulting ball arise from the air spring aspects provided by the combined features.</p>

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Applicant
10/08/2018			
1	19487	Bottle (Class-03)	Paramount Food & Beverages (Pvt) Ltd
2	19488	Display Panel(CLASS-NILL)	Brita GmbH
3	19489	Water Purifier(Class-Nill)	Brita GmbH
4	19490	Dummy	Dummy
5	19491	Water Purifier(Class-Nill)	Brita GmbH
6	19492	Water Purifier(Class-Nill)	Brita GmbH
17/08/2018			
1.	19493	Razor Cartridge	Dorco Co., Ltd.
2.	19494	Razor Cartridge	Dorco Co., Ltd.
3.	19495	Panit Brush Handle (Class No. 3)	Faraz Ibrahim

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Applicant
<u>10/08/2018</u>			
1.	19164	MOBILE PHONE (Class-01)	Beijing Xiaomi Mobile Software Co., Ltd
2.	19165	MOBILE PHONE (Class-01)	Beijing Xiaomi Mobile Software Co., Ltd
3.	19166	MOBILE PHONE (Class-01)	Beijing Xiaomi Mobile Software Co., Ltd
<u>13/08/2018</u>			
4.	19188	MOBILE PHONE (Class-01)	Beijing Xiaomi Mobile Software Co., Ltd



(Dr. Muhammad Fayyaz Ahmad)
 Controller of Patents
 & Registrar of Designs
 Ph: 99230591